检验医学 ›› 2026, Vol. 41 ›› Issue (2): 163-168.DOI: 10.3969/j.issn.1673-8640.2026.02.010

• 论著 • 上一篇    下一篇

术前血清lncRNA CDKN2B-AS1、miR-383-5p在甲状腺癌N分期和术后复发评估中的价值

刘星星1, 杨寒1, 尹迪2()   

  1. 1.南阳南石医院内分泌科河南 南阳 473006
    2.南阳南石医院消化内科河南 南阳 473006
  • 收稿日期:2024-08-13 修回日期:2025-05-15 出版日期:2026-02-28 发布日期:2026-03-06
  • 通讯作者: 尹 迪,E-mail:13462626852@139.com
  • 作者简介:刘星星,女,1987年生,学士,主治医师,主要从事内分泌疾病的诊治工作。

Role of preoperative serum lncRNA CDKN2B-AS1 and miR-383-5p in assessing N stage and postoperative recurrence of thyroid cancer

LIU Xingxing1, YANG Han1, YIN Di2()   

  1. 1. Department of EndocrinologyNanshi Hospital of NanyangNanyang 473006,Henan, China
    2. Department of GastroenterologyNanshi Hospital of NanyangNanyang 473006,Henan, China
  • Received:2024-08-13 Revised:2025-05-15 Online:2026-02-28 Published:2026-03-06

摘要:

目的 探讨术前血清长链非编码RNA(lncRNA)CDKN2B-AS1、miR-383-5p表达与甲状腺癌N分期和术后复发的关系。方法 选取2021年4月—2023年5月南阳南石医院甲状腺癌患者104例、良性甲状腺疾病患者129例(对照组)。收集所有患者的临床资料和实验室指标检测结果,并检测术前血清lncRNA CDKN2B-AS1、miR-383-5p相对表达量。根据最终病理学检查结果将甲状腺癌患者分为N0期组(61例)和N1期组(43例)。对甲状腺癌患者术后随访1年,根据复发情况分为未复发组(71例)和复发组(33例)。采用受试者工作特征(ROC)曲线评价各项指标判断甲状腺癌患者术前N分期和术后复发的效能。采用多因素Logistic回归分析评估甲状腺癌患者术后复发的影响因素。结果 与对照组比较,N0期组、N1期组术前血清lncRNA CDKN2B-AS1相对表达量均升高(P<0.05),miR-383-5p相对表达量均降低(P<0.05)。与N0期组比较,N1期组术前血清lncRNA CDKN2B-AS1相对表达量升高(P<0.05),miR-383-5p相对表达量降低(P<0.05)。复发组术前N1期占比、甲状腺球蛋白(Tg)和lncRNA CDKN2B-AS1均高于未复发组(P<0.001),miR-383-5p低于未复发组(P<0.001);其他各项指标2个组之间差异均无统计学意义(P>0.05)。术前血清lncRNA CDKN2B-AS1、miR-383-5p单项检测和联合检测判断甲状腺癌N1分期的AUC分别为0.809、0.814、0.919,判断甲状腺癌术后复发的AUC分别为0.856、0.833、0.962;Tg判断甲状腺癌术后复发的AUC为0.776。lncRNA CDKN2B-AS1升高、miR-383-5p降低、术前N1分期是甲状腺癌患者术后复发的独立危险因素[比值比(OR)分别为2.914、0.826、2.902,95%可信区间(CI)分别为1.494~5.685、0.739~0.924、1.499~5.618,P<0.01]。结论 甲状腺癌患者术前血清lncRNA CDKN2B-AS1、miR-383-5p表达与N分期和术后复发密切相关,或可作为甲状腺癌病情和预后评估的生物学指标。

关键词: 长链非编码RNA CDKN2B-AS1, 微小RNA-383-5p, N分期, 复发, 甲状腺癌

Abstract:

Objective To investigate the relationship between the expression of preoperative serum long non-coding RNA(lncRNA) CDKN2B-AS1 and miR-383-5p and the N stage and postoperative recurrence of thyroid cancer. Methods A total of 104 patients with thyroid cancer and 129 patients with benign thyroid diseases(control group) were enrolled from Nanshi Hospital of Nanyang from April 2021 to May 2023. The clinical data and laboratory determination results were collected,and the relative expression levels of preoperative serum lncRNA CDKN2B-AS1 and miR-383-5p were determined. According to the final pathological examination results,the patients were classified into N0 stage group(61 cases) and N1 stage group(43 cases). The patients with thyroid cancer were followed up for 1 year after surgery,and the recurrence situation was classified into non-recurrence group(71 cases) and recurrence group(33 cases). Receiver operating characteristic(ROC) curve was used to evaluate the efficacy of various indicators in determining the preoperative N stage and postoperative recurrence of thyroid cancer patients. Multivariate Logistic regression analysis was used to evaluate the influencing factors of postoperative recurrence in thyroid cancer patients. Results Compared with control group,the relative expression levels of preoperative serum lncRNA CDKN2B-AS1 in N0 stage group and N1 stage group were increased(P<0.05),and the relative expression levels of miR-383-5p were decreased(P<0.05). Compared with N0 stage group,the relative expression levels of lncRNA CDKN2B-AS1 in N1 stage group were increased(P<0.05),and the relative expression levels of miR-383-5p were decreased(P<0.05). The preoperative N1 stage proportion,thyroglobulin(Tg) and lncRNA CDKN2B-AS1 in recurrence group were higher than those in non-recurrence group(P<0.001),and miR-383-5p was lower than that in non-recurrence group(P<0.001). There was no statistical significance in the other indicators between the 2 groups(P>0.05). The areas under curves(AUC) of single and combined determinations of lncRNA CDKN2B-AS1 and miR-383-5p for determining the N1 stage of thyroid cancer and the AUC for determining postoperative recurrence were 0.809,0.814,0.919 and 0.856,0.833,0.962,respectively. The AUC of Tg for determining postoperative recurrence was 0.776. The lncRNA CDKN2B-AS1 increasing,miR-383-5p decreasing and preoperative N1 stage were independent risk factors for postoperative recurrence in thyroid cancer patients [odds ratios(OR) were 2.914,0.826 and 2.902,95% confidence intervals(CI) were 1.494-5.685,0.739-0.924 and 1.499-5.618,P<0.01]. Conclusions The expression of preoperative serum lncRNA CDKN2B-AS1 and miR-383-5p in thyroid cancer patients is related to the N stage and postoperative recurrence,and they may be used as biological indicators for the assessment of the condition and prognosis of thyroid cancer.

Key words: Long non-coding RNA CDKN2B-AS 1, MicroRNA-383-5p, N stage, Recurrence, Thyroid cancer

中图分类号: